Varicose Veins disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

VARIX MCID: VRC005 MIFTS: 60	Varicose Veins (VARIX) Categories: Blood diseases, Cardiovascular diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Varicose Veins

MalaCards integrated aliases for Varicose Veins:

Name: Varicose Veins ⁵⁷ ¹¹ ⁵ ⁴¹ ⁴³ ¹⁴ ⁶³ ⁶³ ⁷⁵

Varices ¹¹ ¹⁴

Venous Ectasia ¹¹

Venous Varices ¹¹

Varicosity ⁷¹

Varix ¹¹

Characteristics:

Inheritance:

Multifactorial vs autosomal or X-linked dominant ⁵⁷

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Skin diseases Blood diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the circulatory system

Diseases of veins

Chronic peripheral venous insufficiency of lower extremities

Lower limb varicose veins

Varicose veins with great saphenous reflux

Varicose veins with non-truncal reflux

Varicose veins with small saphenous reflux

External Ids:

Disease Ontology ¹¹ DOID:799

OMIM® ⁵⁷ 192200

MeSH ⁴³ D014648

NCIt ⁴⁹ C35114

SNOMED-CT ⁶⁸ 276504003

MedGen ⁴⁰ C0042345

SNOMED-CT via HPO ⁶⁹ 128060009 12856003 399989005

ICD11 ³³ 1150748505 1819317628 1929651751

UMLS ⁷¹ C0042345

Sources

Summaries for Varicose Veins

MedlinePlus: ⁴¹ Varicose veins are swollen, twisted veins that you can see just under the skin. They usually occur in the legs, but also can form in other parts of the body. Hemorrhoids are a type of varicose vein. Your veins have one-way valves that help keep blood flowing toward your heart. If the valves are weak or damaged, blood can back up and pool in your veins. This causes the veins to swell, which can lead to varicose veins. Varicose veins are very common. You are more at risk if you are older, are female, have obesity, don't exercise, or have a family history of varicose veins. They can also be more common in pregnancy. Doctors often diagnose varicose veins from a physical exam. Sometimes you may need additional tests. Exercising, losing weight, elevating your legs when resting, and not crossing them when sitting can help keep varicose veins from getting worse. Wearing loose clothing and avoiding long periods of standing can also help. If varicose veins are painful or you don't like the way they look, your doctor may recommend procedures to remove them. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Varicose Veins, also known as varices, is related to klippel-trenaunay-weber syndrome and telangiectasis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Varicose Veins is VV (Varicose Veins), and among its related pathways/superpathways are Innate Immune System and Signal Transduction. The drugs Hesperidin and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and heart, and related phenotypes are varicose veins and homeostasis/metabolism

PubMed Health : ⁶³ Varicose veins: Varicose (VAR-i-kos) veins are swollen, twisted veins that you can see just under the surface of the skin. These veins usually occur in the legs, but they also can form in other parts of the body. Varicose veins are a common condition. They usually cause few signs and symptoms. Sometimes varicose veins cause mild to moderate pain, blood clots, skin ulcers (sores), or other problems.

Disease Ontology: ¹¹ A vein disease that is characterized by swollen, twisted veins visible just under the surface of the skin.

Wikipedia: ⁷⁵ Varicose veins, also known as varicoses, are a medical condition in which superficial veins become... more...

More information from OMIM: 192200

Sources

Related Diseases for Varicose Veins

Diseases related to Varicose Veins via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1035)

#	Related Disease	Score	Top Affiliating Genes
1	klippel-trenaunay-weber syndrome	32.6	VEGFA SERPINC1 FOXC2 F2
2	telangiectasis	32.3	VEGFA TNF ELN
3	budd-chiari syndrome	32.1	VWF SERPINC1 MTHFR F2
4	varicocele	32.0	VEGFA TNF SHBG MTHFR IL6 HIF1A
5	pelvic varices	31.9	TNF SHBG MIR202 IL6
6	venous insufficiency	31.9	VWF VEGFA TIMP2 TIMP1 MTHFR MMP9
7	chronic venous insufficiency	31.9	VWF SERPINC1 FOXC2 F2 ELN
8	thrombophlebitis	31.8	VWF SERPINC1 MTHFR F2
9	thrombophilia due to thrombin defect	31.8	VWF SERPINC1 MTHFR F2
10	post-thrombotic syndrome	31.4	VWF SERPINC1 F2
11	pulmonary embolism	31.3	VWF SERPINC1 MTHFR F2
12	vascular disease	31.3	VWF VEGFA TNF TIMP2 TIMP1 SERPINC1
13	portal hypertension	31.3	TNF F2 ELN
14	thrombosis	31.2	VWF SERPINC1 MTHFR F2
15	hemorrhoid	31.2	TNF IL6 F2
16	thrombophilia	31.0	VWF SERPINC1 MTHFR F2
17	liver cirrhosis	31.0	TNF TIMP2 TIMP1 SERPINC1 IL6 F2
18	cellulitis	31.0	TNF IL6 F2
19	schistosomiasis	30.9	VEGFA TNF F2 BCL2
20	alcohol use disorder	30.9	TNF IL6 F2
21	vein disease	30.9	VWF VEGFA TNF TIMP1 SERPINC1 MTHFR
22	factor viii deficiency	30.8	VWF SERPINC1 F2
23	inguinal hernia	30.8	TIMP2 MMP9 MMP2 MMP1 IL6 F2
24	hepatitis b	30.8	TNF MMP9 IL6 F2 BCL2
25	portal vein thrombosis	30.8	VWF SERPINC1 MTHFR F2
26	sclerosing cholangitis	30.7	TNF IL6 F2
27	fasciitis	30.7	TNF MMP1 IL6
28	non-alcoholic steatohepatitis	30.7	TNF TIMP1 IL6
29	melanoma, uveal	30.7	VEGFA MMP2 HIF1A BCL2
30	pyoderma	30.7	TNF MMP9 MMP1
31	pyoderma gangrenosum	30.7	TNF MMP9 MMP1
32	cavernous hemangioma	30.7	VWF VEGFA SERPINC1 F2
33	cholangitis, primary sclerosing	30.7	TNF TIMP1 IL6 F2
34	alcoholic liver cirrhosis	30.6	TNF IL6 F2
35	peptic ulcer disease	30.6	VWF TNF IL6 F2
36	necrotizing fasciitis	30.6	TNF IL6 F2
37	patent foramen ovale	30.6	VWF SERPINC1 MTHFR IL6 F2 ELN
38	aspiration pneumonia	30.6	TNF IL6 F2
39	esophageal cancer	30.6	VEGFA TNF MMP9 MMP2 MMP1 IL6
40	esophageal varix	30.5	SERPINC1 LGALS3BP F2
41	congestive heart failure	30.5	VWF VEGFA TNF MMP9 IL6
42	angiodysplasia	30.5	VWF VEGFA F2
43	peripheral vascular disease	30.5	VWF VEGFA TNF SERPINC1 MTHFR IL6
44	peripheral artery disease	30.5	VWF VEGFA TNF IL6
45	transient cerebral ischemia	30.5	VWF SERPINC1 MTHFR IL6 F2 BCL2
46	cutis laxa	30.5	MMP9 MMP2 MMP1 ELN
47	thrombocytopenia	30.5	VWF VEGFA TNF SERPINC1 MTHFR MMP9
48	arteriovenous malformation	30.4	VWF VEGFA F2
49	osteoarthritis	30.4	TNF TIMP1 MMP9 MMP1 IL6
50	hemangioma	30.4	VWF VEGFA MMP9 IL6 HIF1A F2

Graphical network of the top 20 diseases related to Varicose Veins:

Sources

Symptoms & Phenotypes for Varicose Veins

Human phenotypes related to Varicose Veins:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	varicose veins ³⁰			HP:0002619

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Vascular:
varicose veins

Misc:
twice as frequent in females as in males

Clinical features from OMIM®:

192200 (Updated 08-Dec-2022)

UMLS symptoms related to Varicose Veins:

angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Varicose Veins:

⁴⁵ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.36	BCL2 ELN F2 FOXC2 HIF1A IL6
2	nervous system	MP:0003631	10.32	BCL2 F2 FOXC2 HIF1A IL6 MMP2
3	muscle	MP:0005369	10.22	BCL2 ELN F2 FOXC2 HIF1A IL6
4	cardiovascular system	MP:0005385	10.21	BCL2 ELN F2 FOXC2 HIF1A IL6
5	immune system	MP:0005387	10.2	BCL2 F2 FOXC2 HIF1A IL6 LGALS3BP
6	neoplasm	MP:0002006	10.18	BCL2 HIF1A IL6 MMP1 MMP2 MMP9
7	renal/urinary system	MP:0005367	10.15	BCL2 FOXC2 HIF1A IL6 MMP2 MMP9
8	digestive/alimentary	MP:0005381	10.1	BCL2 F2 FOXC2 HIF1A IL6 MMP2
9	limbs/digits/tail	MP:0005371	10	HIF1A MMP9 MTHFR TIMP1 TIMP2 TNF
10	respiratory system	MP:0005388	9.96	ELN F2 FOXC2 HIF1A IL6 MMP2
11	skeleton	MP:0005390	9.9	ELN F2 FOXC2 HIF1A IL6 MMP2
12	vision/eye	MP:0005391	9.7	BCL2 FOXC2 HIF1A IL6 MMP2 MMP9
13	mortality/aging	MP:0010768	9.47	BCL2 ELN F2 FOXC2 HIF1A IL6

Sources

Drugs & Therapeutics for Varicose Veins

PubMed Health treatment related to Varicose Veins: ⁶³

Varicose veins are treated with lifestyle changes and medical procedures. The goals of treatment are to relieve symptoms, prevent complications, and improve appearance. If varicose veins cause few symptoms, your doctor may simply suggest making lifestyle changes. If your symptoms are more severe, your doctor may recommend one or more medical procedures. For example, you may need a medical procedure if you have a lot of pain, blood clots, or skin disorders caused by your varicose veins. Some people who have varicose veins choose to have procedures to improve how their veins look. Although treatment can help existing varicose veins , it can't keep new varicose veins from forming.

Drugs for Varicose Veins (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hesperidin

Approved, Investigational

Phase 4

520-26-3

53477767

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Somatostatin

Approved, Investigational

Phase 4

38916-34-6, 51110-01-1

53481605 16129706

Mepivacaine

Approved, Vet_approved

Phase 4

96-88-8, 1722-62-9

4062

Warfarin

Approved

Phase 4

81-81-2, 129-06-6

54678486

Nadroparin

Approved, Investigational

Phase 4

Ethanolamine oleate

Approved

Phase 4

2272-11-9

Terlipressin

Approved, Investigational

Phase 4

14636-12-5

72081

Ceftriaxone

Approved

Phase 4

73384-59-5

5479530

Ertapenem

Approved, Investigational

Phase 4

153832-46-3

150610

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Octreotide

Approved, Investigational

Phase 4

83150-76-9

383414 6400441

Carvedilol

Approved, Investigational

Phase 4

72956-09-3

2585

Analgesics

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Analgesics, Non-Narcotic

Phase 4

Anti-Inflammatory Agents

Phase 4

Vasoconstrictor Agents

Phase 4

Hormone Antagonists

Phase 4

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Heparinoids

Phase 4

Salicylates

Phase 4

Proton Pump Inhibitors

Phase 4

Anti-Arrhythmia Agents

Phase 4

Anti-Infective Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Anti-Bacterial Agents

Phase 4

Anesthetics, Local

Phase 4

Bronchodilator Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Anti-Asthmatic Agents

Phase 4

Sodium Channel Blockers

Phase 4

Respiratory System Agents

Phase 4

Mydriatics

Phase 4

Sympathomimetics

Phase 4

Diuretics, Potassium Sparing

Phase 4

Epinephryl borate

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Gastrointestinal Agents

Phase 4

Antioxidants

Phase 4

Protective Agents

Phase 4

Neurotransmitter Agents

Phase 4

Adrenergic Agents

Phase 4

Hormones

Phase 4

Adrenergic beta-Antagonists

Phase 4

Interventional clinical trials:

(show top 50) (show all 324)

#	Name	Status	NCT ID	Phase	Drugs
1	Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices	Unknown status	NCT04074473	Phase 4	propranolol
2	Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices	Unknown status	NCT02740166	Phase 4	propranolol
3	The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices	Unknown status	NCT01287702	Phase 4
4	The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial	Unknown status	NCT02385422	Phase 4	Carvedilol;Propranolol
5	Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome	Unknown status	NCT04358497	Phase 4	Diosmin / Hesperidin;Ibuprofen 400 mg
6	Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial	Unknown status	NCT02695732	Phase 4	Carvedilol
7	The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial	Unknown status	NCT02638415	Phase 4	Carvedilol
8	Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma	Unknown status	NCT01451658	Phase 4	propranolol
9	Comparison of Surgery Versus Foam Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis	Completed	NCT02010723	Phase 4	sclerotherapy with aethoxysclerol foam
10	A Randomized Triple-blind Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Sclerotherapy in Treatment of Reticular Veins at the Lower Limbs.	Completed	NCT02054325	Phase 4	Polidocanol with Glucose;Glucose
11	Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial	Completed	NCT02657252	Phase 4	Glucose;Polidocanol with Glucose
12	Efficacy of Alkalinised 2% Mepivacaine for Local Infiltration Anesthesia, in Ambulatory Phlebectomy	Completed	NCT01611324	Phase 4	Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%;Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%
13	Multicenter Study to Evaluate Pain Following Treatment of Varicose Vein With Varithena® Compared to Radiofrequency Ablation	Completed	NCT02462720	Phase 4	Varithena®
14	PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL	Completed	NCT01893541	Phase 4	PROPRANOLOL
15	Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient	Completed	NCT02346058	Phase 4	Esarin Gel
16	Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection	Completed	NCT00799851	Phase 4	cyanoacrylate injection
17	Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial	Completed	NCT02119884	Phase 4	Terlipressin;Octreotide
18	Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices	Completed	NCT00534677	Phase 4	Terlipressin;Octreotide
19	Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices	Completed	NCT01291277	Phase 4
20	Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed	Completed	NCT00369694	Phase 4	Terlipressin;Terlipressin & then Dummy
21	Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding	Completed	NCT00838864	Phase 4	ceftrioxone
22	Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension	Completed	NCT01059396	Phase 4	propranolol;carvedilol;placebo
23	Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding	Completed	NCT02504723	Phase 4	carvedilol;cyanoacrylate
24	A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding	Completed	NCT01112852	Phase 4	pantoloc 40 mg;somatostatin or terlipressin
25	Initiation of NWS Anticoagulation Therapy After Oesophageal Variceal Band Ligation Was Safe in Portal Vein Thrombosis Patients With Cirrhosis and Acute Variceal Bleeding: A Multi-central Randomized Controlled Trial	Completed	NCT04976543	Phase 4	nadroparin calcium-warfarin sequential anticoagulation
26	Randomised Controlled Trial of Foam Sclerotherapy Versus Ambulatory Phlebectomy for the Treatment of Varicose Vein Tributaries	Recruiting	NCT03416413	Phase 4	Foam sclerotherapy
27	Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices	Recruiting	NCT01970748	Phase 4	Propranolol
28	Beta-blockers or Placebo for Primary Prophylaxis of Oesophageal Varices (BOPPP Trial). A Blinded, Multi-centre, Clinical Effectiveness and Cost-effectiveness Randomised Controlled Trial	Recruiting	NCT03776955	Phase 4	Carvedilol
29	Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study	Recruiting	NCT03624517	Phase 4	Octreotide
30	Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker	Recruiting	NCT01298271	Phase 4	propranolol
31	Antibiotic Prophylaxis in Patients Undergoing Endoscopic Injection of Cyanoacrylate for Primary and Secondary Prevention of Gastric Variceal Bleeding	Recruiting	NCT04140578	Phase 4	Ertapenem
32	A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency	Active, not recruiting	NCT02627846	Phase 4	Lidocaine with 1:200,000 epinephrine solution;Sodium Bicarbonate;Sodium Tetradecyl Sulphate
33	A Phase 4 Randomized Trial Comparing Varithena to Endothermal Ablation for the Treatment of the Great Saphenous Vein	Not yet recruiting	NCT05312970	Phase 4	Varithena®
34	Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed: A Randomized Controlled Study	Not yet recruiting	NCT05199038	Phase 4	Octreotide
35	Banding Ligation With Carvedilol vs. Carvedilol for the Prevention of First Bleeding in Cirrhotics With Moderate Varices	Terminated	NCT01383044	Phase 4	carvedilol
36	Effect of Polidocanol Endovenous Microfoam (PEM) Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in Venous Leg Ulcers (VLUs)	Withdrawn	NCT02988063	Phase 4	Polidocanol Endovenous Microfoam (PEM)
37	A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency.	Withdrawn	NCT02010437	Phase 4	Sodium Tetradecyl Sulphate (STS)
38	Randomized Single Center Comparative Study of the Treatment of Insufficient Greater Saphenous Vein: Surgery vs Ultrasound Guided Sclerotherapy With Foam and Endovenous Laser Therapy	Unknown status	NCT00529672	Phase 3
39	Scleroligation is a Safe and Effective New Technique for Eradication of Gastroesophageal Varices.	Unknown status	NCT02646202	Phase 3
40	A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding	Unknown status	NCT01717612	Phase 3	Thrombin;Histoacryl
41	Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices	Unknown status	NCT01897051	Phase 2, Phase 3	Rifaximin + propranolol;Propranolol + Placebo
42	COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST	Unknown status	NCT01134692	Phase 3	Propranolol, Norfloxacin, VSL#3
43	Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol	Unknown status	NCT02508623	Phase 3	Rifaximin;Placebo
44	Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices	Unknown status	NCT03388125	Phase 3	Injection Sclerotherapy;N-butyl-2-cyanoacrylate
45	A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy	Unknown status	NCT01618890	Phase 3
46	Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV)	Unknown status	NCT02853526	Phase 3	Propranolol;Warfarin
47	A Randomized, Single Blind, Placebo Controlled, Multicenter Study to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence.	Completed	NCT00758420	Phase 2, Phase 3	Varisolve (Polidocanol Endovenous Microfoam);Agitated Saline
48	A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence	Completed	NCT01072877	Phase 3	Polidocanol injectable foam (PEM);Placebo Vehicle
49	A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"	Completed	NCT01231373	Phase 3	polidocanol injectable foam, 0.125%;polidocanol injectable foam, 0.5%;polidocanol injectable foam, 1.0%;Vehicle
50	Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices	Completed	NCT00161915	Phase 3	Fibrin Sealant

Search NIH Clinical Center for Varicose Veins

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Sodium Morrhuate

Sodium Tetradecyl Sulfate

Cochrane evidence based reviews: varicose veins

Sources

Genetic Tests for Varicose Veins

Sources

Anatomical Context for Varicose Veins

Organs/tissues related to Varicose Veins:

MalaCards : Liver, Skin, Heart, Lung, Spleen, Smooth Muscle, Kidney

Sources

Publications for Varicose Veins

Articles related to Varicose Veins:

(show top 50) (show all 22608)

#	Title	Authors	PMID	Year
1	Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. ⁶² ⁵⁷	Ng MY...Lymphoedema Consortium	15744037	2005
2	A contribution to the problem of the inheritance of primary varicose veins. ⁶² ⁵⁷	Matousek V...Prerovsky I	4435791	1974
3	Genetics of varicose veins of the lower extremities. ⁶² ⁵⁷	Hauge M...Gundersen J	5365895	1969
4	The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma. ⁶² ⁴¹	Kondo T...Kato N	36456830	2022
5	Is There an Association between Variceal Bleed and Helicobacter pylori Infection in Cirrhotic Patients with Portal Hypertension?: A prospective cohort study. ⁶² ⁴¹	Varuna S...Mahalakshmy T	36407709	2022
6	Familiar congenital absence of valves in the deep leg veins. ⁵⁷	Leu HJ	4426629	1974
7	The heredity of venous insufficiency. ⁵⁷	ARNOLDI CC	13561707	1958
8	Acute gastrointestinal bleeding: A comparison between variceal and nonvariceal gastrointestinal bleeding. ⁴¹	Ratiu I...Sirli R	36397398	2022
9	Endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in patients with cirrhosis and esophageal varices. ⁶²	Mochimaru T...Ohira H	35898831	2023
10	Percutaneous transhepatic obliteration for life-threatening bleeding after endoscopic variceal ligation in a patient with severe esophagogastric varices. ⁶²	Chikamori F...Sharma N	36471734	2023
11	Coil-assisted retrograde transvenous obliteration of gastric varices by an inverted catheter tip technique via the pericardiophrenic vein. ⁶²	Asano K...Miki Y	36340230	2023
12	Biochemical markers to predict the development of gastrointestinal bleeding and esophageal varices after portoenterostomy in biliary atresia. ⁶²	Sumida W...Uchida H	36114864	2022
13	Pipeline Esophagogastric Varices Secondary to Extrahepatic Portal Vein Obstruction Treated Endoscopically with the Assistance of Transileocolic Obliteration. ⁶²	Yokoyama S...Ishigami M	35491134	2022
14	Successful treatment of rectal varices with antegrade transvenous sclerotherapy via the splenorenal shunt from the transjugular approach. ⁶²	Pas M...Miki Y	36204409	2022
15	Transesophageal endoscopic ultrasound-guided coil and cyanoacrylate treatment of challenging esophageal varices bleeding associated with CREST syndrome ulcerative esophagitis. ⁶²	Rivory J...Valette PJ	35523221	2022
16	Bleeding Complications from Transesophageal Echocardiography for Liver Transplantation: A Systematic Review. ⁶²	Dunkman WJ...Manning MW	35993392	2022
17	Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up. ⁶²	Badia Aranda E...Gomez Camarero J	35189262	2022
18	In vitro and in vivo evaluation of a novel wired transmission magnetically controlled capsule endoscopy system for upper gastrointestinal examination. ⁶²	Zhang Y...Huang X	36112221	2022
19	Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial. ⁶²	Santos LAA...Romeiro FG	35767173	2022
20	Gender differences in esophageal variceal bleeding in the United States. ⁶²	Sohal A...Prajapati D	35930410	2022
21	Detection of residual varicose veins with near infrared light in the early period after varicose surgery and near infrared light assisted sclerotherapy. ⁶²	Kahraman N...Goncu MT	34715769	2022
22	Peri-procedural thromboprophylaxis in the prevention of DVT in varicose vein interventions: A systematic review and meta-analysis. ⁶²	Alameer A...Kheirelseid EAH	35589498	2022
23	Pilot single-arm study to investigate the efficacy and safety of endovenous Microwave ablations for treatment of varicose veins in Singapore - one year results of the MAESTRO registry. ⁶²	Tang TY...Wong JCL	36154744	2022
24	Septicemia after cyanoacrylate glue closure of varicose veins. ⁶²	Nishizawa M...Kudo T	36262917	2022
25	Comprehensive overview of the venous disorder known as pelvic congestion syndrome. ⁶²	Balabuszek K...Pietura R	34935563	2022
26	FOVELASS - a randomised trial of EVLA versus Polidocanol Foam for SSV incompetence. ⁶²	Hamel-Desnos C...Abbadie F	36470312	2022
27	[Current diagnostics and treatment of portal hypertension]. ⁶²	Zimmermann HW...Bruns T	36374293	2022
28	A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC. ⁶²	Larrey E...Allaire M	36254617	2022
29	Acute Variceal Hemorrhage and Airway Obstruction in a Patient With Reinke's Edema. ⁶²	Raskin J...Nasseri S	36052403	2022
30	Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography. ⁶²	Cicero G...Mazziotti S	36212766	2022
31	Variceal ligation in decompensated cirrhosis before esophageal endoscopic submucosal dissection. ⁶²	Robbins G...Raina A	36467528	2022
32	Identification of risk factors for upper gastrointestinal bleeding in intensive care unit patients (GIBICU study). ⁶²	Poszler A...Lahmer T	35771587	2022
33	MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension. ⁶²	Kennedy P...Taouli B	35727321	2022
34	Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning-measured Spleen Volume at CT. ⁶²	Choi SJ...Jang JK	35943338	2022
35	A deceptive mass on neonatal ultrasound and a fetal brain MRI-confirmed complex dural arteriovenous fistula postnatally: illustrative case. ⁶²	Varney ET...Nichols T	36471579	2022
36	Dural arteriovenous fistula of the craniocervical junction along the first cervical nerve: A single-center experience and review of the literature. ⁶²	Iampreechakul P...Siriwimonmas S	36470044	2022
37	Intracranial dural arteriovenous fistula: a comprehensive review of the history, management, and future prospective. ⁶²	Alkhaibary A...Khairy S	36374476	2022
38	Intra-amniotic umbilical vein varix: A case report and review of the literature. ⁶²	Nasser BH...Jadaon JE	36323645	2022
39	Pulmonary varix clearly demonstrated by 3D-CT before pulmonary angiography. ⁶²	Yamaguchi B...Yokoo K	36105839	2022
40	An Unusual Complication of Endoscopic Cyanoacrylate Injection for Gastric Varix. ⁶²	Prasoppokakorn T...Rerknimitr R	35671805	2022
41	Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ⁶²	Tapper EB...Parikh ND	35262903	2022
42	Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency. ⁶²	Globig AM...Warnatz K	35821451	2022
43	Emergent TIPS as a first-line therapy in advanced cirrhotic patients with acute gastroesophageal variceal bleeding. ⁶²	Li WC...Zhu XL	36414117	2022
44	Screening and management of portal hypertension in advanced hepatocellular carcinoma: a French practice survey. ⁶²	Allaire M...Thabut D	36455860	2022
45	Nonalcoholic Fatty Liver Disease-A Concise Review of Noninvasive Tests and Biomarkers. ⁶²	Bassal T...Assy N	36355154	2022
46	Comparing large-volume band ligators and cyanoacrylate injection for gastric variceal eradication: A prospective study. ⁶²	Shi D...Liu J	36401384	2022
47	Polymorphisms in some proinflammatory genes (TNFα and β, IL-1β, IL-6, ADAM17) in severe chronic venous disease. ⁶²	Slonkova V...Vasku V	36420762	2022
48	Age, Sex, and Body Mass Index Should Be Considered When Assessing Spleen Length in Patients with Compensated Advanced Chronic Liver Disease. ⁶²	Lee HA...Seo YS	36424721	2022
49	Routine use of concurrent fluoroscopic imaging during superficial endovenous interventions: A position statement of the International Union of Phlebology (UIP), the Australasian College of Phlebology (ACP), the Australia and New Zealand Society for Vascular Surgery (ANZSVS), the American Venous Forum (AVF), the American Vein and Lymphatic Society (AVLS), the European College of Phlebology (ECoP) and the Interventional Radiology Society of Australasia (IRSA). ⁶²	Parsi K...van Rij A	35970306	2022
50	PHIL® (precipitating hydrophobic injectable liquid): retrospective multicenter experience on 178 patients in peripheral embolizations. ⁶²	Giurazza F...Lucatelli P	36070065	2022

Sources

Genes for Varicose Veins

Genes related to Varicose Veins (0 elite genes):

(show all 40)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	VV	Varicose Veins	Genetic Locus	17.63	GeneCards inferred via : Publications Gene name (show sections)
2	F2	Coagulation Factor II, Thrombin	Protein Coding	16.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
3	MIR202	MicroRNA 202	RNA Gene	14.84	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
4	MMP9	Matrix Metallopeptidase 9	Protein Coding	14.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	SERPINC1	Serpin Family C Member 1	Protein Coding	14.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	14.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	FOXC2	Forkhead Box C2	Protein Coding	14.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	MMP2	Matrix Metallopeptidase 2	Protein Coding	13.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	TIMP1	TIMP Metallopeptidase Inhibitor 1	Protein Coding	13.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	VWF	Von Willebrand Factor	Protein Coding	13.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	TNF	Tumor Necrosis Factor	Protein Coding	13.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	ELN	Elastin	Protein Coding	13.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	IL6	Interleukin 6	Protein Coding	13.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	13.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MMP1	Matrix Metallopeptidase 1	Protein Coding	13.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	BCL2	BCL2 Apoptosis Regulator	Protein Coding	13.68	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	13.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	LGALS3BP	Galectin 3 Binding Protein	Protein Coding	13.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	13.58	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	SHBG	Sex Hormone Binding Globulin	Protein Coding	13.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	AGGF1	Angiogenic Factor With G-Patch And FHA Domains 1	Protein Coding	13.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	THBD	Thrombomodulin	Protein Coding	13.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	13.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	MMP3	Matrix Metallopeptidase 3	Protein Coding	13.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	FN1	Fibronectin 1	Protein Coding	12.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	ESR1	Estrogen Receptor 1	Protein Coding	12.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	KDR	Kinase Insert Domain Receptor	Protein Coding	12.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	FBN1	Fibrillin 1	Protein Coding	12.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	F5	Coagulation Factor V	Protein Coding	12.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	TIMP3	TIMP Metallopeptidase Inhibitor 3	Protein Coding	12.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	PLAT	Plasminogen Activator, Tissue Type	Protein Coding	12.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	COL3A1	Collagen Type III Alpha 1 Chain	Protein Coding	12.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	PIEZO1	Piezo Type Mechanosensitive Ion Channel Component 1	Protein Coding	12.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	APOA1	Apolipoprotein A1	Protein Coding	12.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	HFE	Homeostatic Iron Regulator	Protein Coding	12.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	KNG1	Kininogen 1	Protein Coding	12.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	CASP9	Caspase 9	Protein Coding	12.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	LGALS3	Galectin 3	Protein Coding	12.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	12.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Varicose Veins

ClinVar genetic disease variations for Varicose Veins:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ELN	NM_000501.4(ELN):c.898A>T (p.Thr300Ser)	SNV	Uncertain Significance	523433	rs766735416	GRCh37: 7:73466262-73466262 GRCh38: 7:74051932-74051932

Sources

Expression for Varicose Veins

Search GEO for disease gene expression data for Varicose Veins.

Sources

Pathways for Varicose Veins

Pathways related to Varicose Veins according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.96	BCL2 F2 HIF1A IL6 MMP1 MMP2
2	Signal Transduction ⁶⁶	13.76	VWF VEGFA TNF MMP9 MMP2 IL6
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.6	VEGFA TNF TIMP1 MMP9 MMP1 IL6
4	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.32	VEGFA TNF TIMP1 MMP9 MMP2 MMP1
5	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.28	VWF VEGFA TIMP1 SERPINC1 MMP1 LGALS3BP
6	Collagen chain trimerization ⁶⁶ Show member pathways Anchoring fibril formation ⁶⁶ Assembly of collagen fibrils and other multimeric structures ⁶⁶ Blood Coagulation Cascade ⁶⁴ Collagen biosynthesis and modifying enzymes ⁶⁶ Collagen degradation ⁶⁶ Collagen formation ⁶⁶ Crosslinking of collagen fibrils ⁶⁶ Intrinsic Prothrombin Activation Pathway ⁶⁴	12.79	SERPINC1 MMP9 MMP2 MMP1 F2
7	Extracellular matrix organization ⁶⁶ Show member pathways Degradation of the extracellular matrix ⁶⁶	12.75	VWF TIMP2 TIMP1 MMP9 MMP2 MMP1
8	Malignant pleural mesothelioma ⁷⁴	12.7	VEGFA MMP9 MMP2 IL6 HIF1A BCL2
9	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.61	TNF TIMP1 MMP2 IL6 F2 BCL2
10	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12.38	TIMP1 SERPINC1 MMP2 MMP1 IL6 F2
11	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.27	TNF MMP9 MMP1 IL6
12	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.16	MMP9 MMP2 HIF1A FOXC2
13	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.15	VEGFA TNF IL6 HIF1A
14	Colorectal Cancer Metastasis ⁶⁴	12.15	IL6 MMP1 MMP2 MMP9 TNF VEGFA
15	Adipogenesis ⁷⁴	12.06	TNF IL6 HIF1A FOXC2
16	CCL18 signaling pathway ⁷⁴	11.9	VEGFA TIMP2 TIMP1 MMP2 IL6
17	Matrix metalloproteinases ⁷⁴ Show member pathways Activation of Matrix Metalloproteinases ⁶⁶ Inhibition of Matrix Metalloproteinases ⁶⁴	11.85	TNF TIMP2 TIMP1 MMP9 MMP2 MMP1
18	Interleukin-6 family signaling ⁶⁶ Show member pathways IL-6-type cytokine receptor ligand interactions ⁶⁶ Immune response Oncostatin M signaling via JAK-Stat in human cells ²² Interleukin-6 signaling ⁶⁶	11.76	VEGFA TIMP1 MMP1 IL6
19	Angiogenesis (CST) ³	11.75	VWF TIMP2 TIMP1 MMP9 MMP2 HIF1A
20	Acute viral myocarditis ⁷⁴	11.74	MMP9 IL6 BCL2
21	AP-1 transcription factor network ⁶¹	11.67	TIMP1 MMP9 MMP1 IL6 HIF1A
22	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.64	VEGFA TNF TIMP1 MMP9 MMP2 MMP1
23	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.63	HIF1A IL6 MMP1 VEGFA
24	ATF-2 transcription factor network ⁶¹	11.61	MMP2 IL6 BCL2
25	Cell adhesion_ECM remodeling ²²	11.59	TIMP2 TIMP1 MMP9 MMP2 MMP1
26	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.57	VEGFA MMP9 MMP2
27	Lung fibrosis ⁷⁴	11.53	ELN IL6 MMP2 MMP9 TIMP1 TNF
28	Interleukin-10 signaling ⁶⁶	11.51	TNF TIMP1 IL6
29	Bladder cancer ⁷⁴	11.48	VEGFA MMP9 MMP2 MMP1
30	Cell adhesion_Cell-matrix glycoconjugates ²²	11.46	TIMP2 MMP9 MMP1 ELN
31	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.43	IL6 MMP1 MMP2 MMP9 TNF VEGFA
32	Validated transcriptional targets of AP1 family members Fra1 and Fra2 ⁶¹	11.39	IL6 MMP1 MMP2 MMP9
33	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.29	IL6 MMP1 TNF
34	Development_Leptin signaling via JAK/STAT and MAPK cascades ²² Show member pathways phospho-PLA2 pathway ⁶⁶	11.29	HIF1A TIMP1 VEGFA
35	amb2 Integrin signaling ⁶¹	11.27	TNF MMP9 MMP2 IL6
36	Immune infiltration in pancreatic cancer ⁷⁴	11.24	VEGFA TNF IL6
37	Prostaglandin signaling ⁷⁴	11.24	VEGFA TNF MMP9 IL6
38	IL1 and megakaryocytes in obesity ⁷⁴	11.16	TIMP2 TIMP1 MMP9 F2
39	Burn wound healing ⁷⁴	11.15	VEGFA TNF TIMP1 MMP9 MMP2 MMP1
40	Overview of nanoparticle effects ⁷⁴	11.08	TNF IL6 BCL2
41	Angiogenesis (WikiPathways) ⁷⁴	11.07	TIMP2 MMP9 HIF1A
42	G-protein signaling_Rap2B regulation pathway ²²	11.02	TNF TIMP2 TIMP1 IL6 ELN BCL2
43	MicroRNA for targeting cancer growth and vascularization in glioblastoma ⁷⁴ Show member pathways Oncostatin M signaling pathway ⁷⁴	10.64	HIF1A VEGFA
44	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.36	TNF IL6

Sources

GO Terms for Varicose Veins

Cellular components related to Varicose Veins according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.3	VWF VEGFA TNF TIMP2 TIMP1 SERPINC1
2	extracellular region	GO:0005576	10.3	ELN F2 IL6 LGALS3BP MMP1 MMP2
3	collagen-containing extracellular matrix	GO:0062023	9.86	ELN F2 LGALS3BP MMP2 MMP9 SERPINC1
4	extracellular matrix	GO:0031012	9.47	VWF VEGFA TIMP2 TIMP1 MMP9 MMP2

Biological processes related to Varicose Veins according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.15	VEGFA TNF TIMP1 MMP9 IL6 HIF1A
2	positive regulation of chemokine production	GO:0032722	10.05	TNF IL6 HIF1A
3	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	10.04	TNF MMP9 MMP2
4	ovarian follicle development	GO:0001541	10.03	VEGFA MMP2 BCL2
5	collagen catabolic process	GO:0030574	10.02	MMP9 MMP2 MMP1
6	positive regulation of peptidyl-serine phosphorylation	GO:0033138	10.01	BCL2 IL6 TNF VEGFA
7	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	9.99	TNF IL6 F2
8	extracellular matrix organization	GO:0030198	9.97	TNF MMP9 MMP2 MMP1 ELN
9	response to hypoxia	GO:0001666	9.96	HIF1A MMP2 MTHFR TNF VEGFA
10	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.91	TNF IL6 HIF1A
11	response to radiation	GO:0009314	9.88	TNF MMP2 BCL2
12	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.84	VEGFA HIF1A
13	connective tissue replacement involved in inflammatory response wound healing	GO:0002248	9.83	HIF1A TIMP1
14	negative regulation of metallopeptidase activity	GO:1905049	9.8	TIMP2 TIMP1
15	hemostasis	GO:0007599	9.76	VWF SERPINC1 F2
16	response to cytokine	GO:0034097	9.7	TIMP2 TIMP1 MMP2 BCL2
17	vascular endothelial growth factor production	GO:0010573	9.43	TNF IL6 HIF1A
18	cellular response to UV-A	GO:0071492	9.23	TIMP1 MMP9 MMP2 MMP1